Vanda Pharmaceuticals designed the Phase 3 study, announced on October 14, 2026, to confirm earlier mid-stage trial results for VQW-765 in patients with social anxiety disorder

552c7ae14

Mental health

Supports emotional wellbeing and psychological resilience through digital tools or professional care access.

3 debates·795 claims·43 news stories

0